Companies › Poseida Therapeutics
3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Mar 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| P-BCMA-ALLO1 allogeneic BCMA-targeted CAR-T cell therapy | BCMA | Phase 1 | Multiple Myeloma | Mar 2029 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T cells targeting CD19 and CD20 | CD19, CD20 | Phase 1 | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Mar 2029 |
| P-MUC1C-ALLO1 Allogeneic CAR-T cell therapy targeting MUC1-C | MUC1 | Phase 1 | Breast Cancer | Apr 2039 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04960579 | P-BCMA-ALLO1 | Phase 1 | Multiple Myeloma | Oncology | Mar 2029 |
| NCT06014762 | P-CD19CD20-ALLO1 | Phase 1 | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Oncology | Mar 2029 |
| NCT03741127 | P-BCMA-ALLO1 | Phase 1 | Multiple Myeloma | Oncology | Aug 2032 |
| NCT05239143 | P-MUC1C-ALLO1 | Phase 1 | Breast Cancer | Oncology | Apr 2039 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.